Key points are not available for this paper at this time.
Incretin-based therapies, known for their efficacy in Type 2 diabetes management, are increasingly explored in the context of Type 1 diabetes due to their ability to modulate insulin and glucagon secretion. This shift in focus has prompted investigations into the potential benefits of Tirzepatide and Semaglutide, a glucagon-like peptide-1 receptor agonist, in managing Type 1 Diabetes. This case series study investigates Tirzepatide and Semaglutide's potential benefits in Type 1 Diabetes management.Our study included 10 T1D patients (30-47 years) using a hybrid care model with physical encounters and remote data monitoring. Patients on insulin were initiated on Semaglutide or Tirzepatide over three months. Data, including baseline characteristics and continuous glucose monitoring (CGM) metrics, were collected. Patients showed a substantial reduction in prandial and basal insulin doses (-25.24%, -29.16%). HbA1c improved from 8.28% to 6.95% in 3 months. Time in Range increased significantly (+42.11%, p=0.002). Overweight/obese patients lost -5.64 kg (p0.001). The initiation of incretin therapy led to a substantial decrease in both bolus and basal insulin requirements, along with noteworthy improvements in HbA1c levels, weight and TIR. These reductions in alignment with ADA recommendations for T1D patients underscore the potential benefits of incretin-based therapies. Dose adjustments, continuous monitoring, and avoiding hypoglycemia were crucial.Preliminary findings suggest incretin therapy as an adjunct to insulin in T1D management, showing reduced insulin requirements, improved glycemic control, and positive weight impacts. However, comprehensive, randomized clinical trials with a larger cohort are needed to validate these outcomes. Disclosure I. Almarzooqi: None. H. Zakaria: None. M. Caccelli: None. Y. Said: None. A. Hashemi: None.
ALMARZOOQI et al. (Fri,) studied this question.